3p0y
From Proteopedia
(Difference between revisions)
Line 11: | Line 11: | ||
===anti-EGFR/HER3 Fab DL11 in complex with domain III of EGFR extracellular region=== | ===anti-EGFR/HER3 Fab DL11 in complex with domain III of EGFR extracellular region=== | ||
+ | |||
+ | <!-- | ||
+ | The line below this paragraph, {{ABSTRACT_PUBMED_22014573}}, adds the Publication Abstract to the page | ||
+ | (as it appears on PubMed at http://www.pubmed.gov), where 22014573 is the PubMed ID number. | ||
+ | --> | ||
+ | {{ABSTRACT_PUBMED_22014573}} | ||
==About this Structure== | ==About this Structure== | ||
- | [[3p0y]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3P0Y OCA]. | + | [[3p0y]] is a 3 chain structure of [[Epidermal Growth Factor Receptor]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3P0Y OCA]. |
+ | |||
+ | ==See Also== | ||
+ | *[[Epidermal Growth Factor Receptor]] | ||
+ | |||
+ | ==Reference== | ||
+ | <ref group="xtra">PMID:022014573</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Receptor protein-tyrosine kinase]] | [[Category: Receptor protein-tyrosine kinase]] |
Revision as of 06:37, 21 March 2012
Contents |
anti-EGFR/HER3 Fab DL11 in complex with domain III of EGFR extracellular region
Template:ABSTRACT PUBMED 22014573
About this Structure
3p0y is a 3 chain structure of Epidermal Growth Factor Receptor with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell. 2011 Oct 18;20(4):472-86. PMID:22014573 doi:10.1016/j.ccr.2011.09.003